HALLE/SAALE, Germany, June 2, 2014 – Probiodrug AG (Probiodrug), today announced that the Company will participate in the second annual Asia Biotech Invest conference, to be held at the Sheraton Hotel & Towers in Hong Kong. The presentation, given by Dr Konrad Glund, Probiodrug’s chief executive officer, will take place at 3:05pm local time on 4 June 2014.
The premier life science investment event in Hong Kong, Asia Biotech Invest is designed to connect global biotech and medtech companies with Asia’s growing community of life science investors and pharma executives to discuss investment and partnership opportunities. For more information on the conference, please visit asiabiotechinvest.com.
Probiodrug is a biopharmaceutical company dedicated to the discovery and development of novel therapeutic solutions to treat people with Alzheimer’s disease. The Company has medical use and composition of matter patents related to the inhibition of glutaminyl cyclase, providing the Company with a dominant position in this field of research. Probiodrug is backed by institutions such as BB Biotech, Edmond de Rothschild Investment Partners, Goodvent/IBG, HBM, TVM Capital, Life Sciences Partners, Biogen Idec New Ventures, CFH Group, funds managed by Wellington Management and private investors.
Probiodrug’s core capabilities are based on its long-standing expertise in the elucidation of the structure and function of enzymes which play a central role in the maturation of hormones. Probiodrug was founded in 1997 by Prof. Dr. Hans-Ulrich Demuth and Dr. Konrad Glund. For more information, please visit www.probiodrug.de.
Dr. Konrad Glund, CEO Tel: +49 (345) 555-9900